Einrichtung-Details

Neurologie und Schmerztherapie - Immanuel Klinik Rüdersdorf

Die Abteilung für Neurologie und Schmerztherapie bietet optimale Möglichkeiten zur Diagnostik und Behandlung von akuten und chronischen Erkrankungen des peripheren und zentralen Nervensystems. Spezialisiert ist die Abteilung dabei auf die Behandlung von Schlaganfällen nach dem Stroke Unit Konzept, Multiple Sklerose und die multimodale Schmerztherapie.

Ausgewählte Publikationen

Publikationsliste (Auswahl)

 

Originalarbeiten

Korsten P, Rademacher JG, Riedel L, Schnitzler EM, Olgemöller U, Seitz CS, Schmidt J, Larsen J, Vasko R. Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography. Front Med 2021; 7: 609595.
IF 2019: 3.9.

Prukop T, Wernick S, Boussicault L, Ewers D, Jäger K, Adam J, Winter L, Quintes S, Linhoff L, Barrantes-Freer A, Bartl M, Czesnik D, Zschüntzsch J, Schmidt J, Primas G, Laffaire J, Rinaudo P, Brureau A, Nabirotchkin S, Schwab MH, Nave KA, Hajj R, Cohen D, Sereda MW. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats. J Neurosci Res. 2020; 98(10): 1933-1952. IF 2019: 4.7.

Zschüntzsch J, Jouvenal P, Zhang Y, Klinker F, Tiburcy M, Liebetanz D, Malzahn D, Brinkmeier H, Schmidt J. Long-term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 2020; 11(4):1018-1031. IF 2018: 10.8.

Korsten P, Rademacher JG, Seitz CS, Zschüntzsch J, Mößner R, Zeisberg M, Olgemöller U, Buck C, Zechel S, Müller GA, Vasko R, Schmidt J. Interdisciplinary case conferences as opportunity for myositis patients? Nervenheilkunde 2019; 38:377-380. IF 2012: 0,3

Capkun G, Schmidt J, Ghosh S, Sharma H, Obadia T, de Vera A, Risson V, Amzal B. Development and validation of a Bayesian survival model for inclusion body myositis. Theor Biol Med Model. 2019; 16(1):17. IF 2018: 1.6

Carstens PO, Schwaibold EMC, Schregel K, Obermaier C, Wrede A, Pauli S, Schmidt J. Recurrent spontaneous pneumothorax in X-linked myotubular myopathy: a new phenotype? Neurol Genet. 2019; 5(3): e3272019. Kein IF.

De Paepe B, Zschüntzsch J, Šokčević T, Weis J, Schmidt J*, De Bleecker JL*. Induction of Osmolyte Pathways in Skeletal Muscle Inflammation: Novel Biomarkers for Myositis. Front Neurol. 2018; 9:846. *equal contribution. IF 2017: 3.5

Herbelet S, De Vlieghere E, Gonçalves A, De Paepe B, Schmidt K, Nys E, Weynants L, Weis J, Van Peer G, Vandesompele J, Schmidt J, De Wever O, De Bleecker JL. Localization and Expression of Nuclear Factor of Activated T-Cells 5 in Myoblasts Exposed to Pro-inflammatory Cytokines or Hyperosmolar Stress and in Biopsies from Myositis Patients. Front Physiol. 2018; 9:126.
IF 2017: 3.4

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Jordan P, Benveniste O, Danieli MG, Dankó K, Thuy NTP, Vázquez-Del Mercado M, Andersson H, De Paepe B, De Bleecker J, Maurer B, Pipitone N, McHugh N, Betteridge Z, New P, Cooper RG, Ollier WE, Lamb JA, Steen Krogh N, Lundberg IE, Chinoy H, On behalf of all EuroMyositis contributors. The  EuroMyositis Registry: An International Collaborative Tool to Facilitate Myositis Research. Ann Rheum Dis 2018;77(1):30-39. IF 2016: 12.8

Smogavec M, Zschüntzsch J, Kress W, Mohr J, Hellen P, Zoll B, Pauli S, Schmidt J. Novel fukutin mutations in limb-girdle muscular dystrophy type 2M with childhood onset. Neurol Genet 2017; 3(4):e167. Kein IF.

Schmidt K, Wienken M, Keller CW, Balcarek P, Münz C, Schmidt J. IL-1β-Induced Accumulation of Amyloid: Macroautophagy in Skeletal Muscle Depends on ERK. Mediators Inflamm. 2017; 2017: 5470831. IF 2015: 3.4

Olthoff A, Carstens PO, Zhang S, von Fintel E, Friede T, Lotz J, Frahm J, Schmidt J. Evaluation of dysphagia by novel real-time magnetic resonance imaging. Neurology 2016; 87: 2132-38.
IF 2015: 8.2

Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol 2016; 16: 48. IF 2015: 2.0

Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, Hilton-Jones D, Kissel JT; Lloyd TE, Lundberg IE, Mastaglia F, Mozaffar T, Needham M, Schmidt J, Sivakumar K, DeMuro C, Tseng BS. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. J Neuromuscul Dis 2016; 3: 67-75. No IF.

Stoeck K, Psychogios MN, Ohlenbusch A, Steinfeld R, Schmidt J. Late-onset metachromatic leukodystrophy with early onset dementia associated with a novel missense mutation in the arylsulfatase A gene. J Alzheimers Dis 2016; 51: 683-687. IF 2014: 4.1

Jones K, Sejersen T, Amato A, Hilton-Jones D, Schmidt J, Wallace A, Badrising U, Rose M, “The IBM Guideline Development Group”. A protocol to develop clinical guidelines for inclusion-body myositis. Muscle Nerve 2016; 53: 503-507. IF 2014: 2.3

Zschüntzsch J, Zhang Y, Klinker F, Makosch G, Klinge L, Malzahn D, Brinkmeier H, Liebetanz, D, Schmidt J. Treatment with human IgG improves the early disease course in a mouse model of Duchenne muscular dystrophy. J Neurochem 2016; 136: 351–362. IF 2014: 4.3

Muth IE, Zschüntzsch J, Kleinschnitz K, Wrede A, Gerhardt E, Balcarek P, Schreiber-Katz O, Zierz S, Dalakas MC, Voll RE, Schmidt J. HMGB1 and RAGE in skeletal muscle inflammation: implications for protein accumulation in inclusion body myositis. Exp Neurol 2015; 271: 189–197. IF 2014: 4.6

Stoeck K, Carstens PO, Jarius S, Raddatz D, Stöcker W, Wildemann B, Schmidt J. Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2015. 2015; 2(3):e86. Kein IF

Zschüntzsch J, Jouvenal P, Zhang Y, Klinker F, Tiburcy M, Malzahn D, Liebetanz D, Brinkmeier H,. Schmidt J. Human immunoglobulin G for experimental treatment of Duchenne muscular dystrophy. Clin. Exp. Immunol. 2014 (178): 132–133. IF 2013: 3.3

Rose MR, …Schmidt J…, ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23: 1044-55. IF 2012: 3.5

Fischer C, Kleinschnitz K, Wrede A, Muth I, Kruse N, Nishino I, Schmidt J. Cell stress molecules in the skeletal muscle of GNE myopathy. BMC Neurol 2013; 13: 24. IF 2011: 2.2

Keller CW, Schmitz M, Münz C, Lünemann JD, Schmidt J. TNF-α upregulates macroautophagic processing of APP/β-amyloid in a human rhabdomyosarcoma cell line. J Neurol Sci 2013; 325: 103-7. IF 2011: 2.4

Zschüntzsch J, Voss J, Creus K, Sehmisch S, Raju R, Dalakas MC, Schmidt J. Provision of an explanation for the inefficacy of immunotherapy in sIBM: Quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum 2012; 64: 4094-103. IF 2011: 7.9

Schmidt J, Barthel K, Zschüntzsch J, Muth IE, Swindle EJ, Hombach A, Sehmisch S, Wrede A, Lühder F, Gold R, Dalakas MC. Nitric oxide stress in sIBM muscle fibres: inhibition of iNOS prevents IL-1β-induced accumulation of β-amyloid and cell death. Brain 2012; 135: 1102-14. IF 2010: 9.2

Weller C, Zschüntzsch J, Makosch G, Metselaar JM, Klinker F, Klinge L, Liebetanz D, Schmidt J. Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes. J Neurosci Res 2012; 90: 1067-77. IF 2010: 3.0

Keller CW, Fokken C, Turville SG, Lünemann A, Schmidt J*, Münz C*, Lünemann JD*. TNF-α induces macroautophagy and regulates MHC Class II expression in human skeletal muscle cells. J Biol Chem 2011; 286: 3970-3980 *equal contribution. IF 2009: 5.3

Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy JAE, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (Campath 1-H) in patients with Inclusion Body Myositis. Brain 2009; 132: 1536-1544. IF 2009: 9.5

Muth IE, Barthel K, Bähr M, Dalakas MC, Schmidt J. Pro-inflammatory cell stress in sIBM muscle: overexpression of αB-crystallin is associated with amyloid precursor protein and accumulation of β-amyloid. J Neurol Neurosurg Psychiatry 2009; 80: 1344-9. IF 2009: 4.9

Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-40. IF 2009: 9.5

Rostasy KM*, Schmidt J*, Bahn E, Pfander T, Piepkorn M, Wilichowski E, Schulz-Schaeffer WJ. Distinct inflammatory properties of late-activated macrophages in inflammatory myopathies. Acta Myol 2008; 27: 49-53. *equal contribution (no IF)

Linker RA, Weller C, Lühder F, Mohr A, Schmidt J, Knauth M, Metselaar JM, Gold R. Liposomal Glucocorticosteroids in Treatment of Chronic Autoimmune Demyelination: Long-term Protective Effects and Enhanced Efficacy of Methlyprednisolone Formulations. Exp. Neurol 2008; 211: 397-406. IF 2009: 3.9

Lunemann JD*, Schmidt J*, Schmid D, Barthel K, Wrede A, Dalakas MC, Münz C. β-amyloid is a Substrate of Macroautophagy in Sporadic Inclusion Body Myositis. Ann Neurol 2007; 61: 476-483; *equal contribution. IF 2009: 9.3

Salajegheh M, Raju R, Schmidt J, Dalakas MC. Upregulation of Thrombospondin-1 (TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis. J Neuroimmunol 2007; 187: 166-74. IF 2009: 2.8

Gelderblom H*, Schmidt J*, Londoño D, Bai Y, Quandt J, Hornung R, Marques A, Martin R, Cadavid D. Role of Interleukin 10 during Persistent Infection with the Relapsing Fever Spirochete Borrelia turicatae. Am J Pathol 2007; 170: 251-62; *equal contribution. IF 2009: 5.7

Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J, Quandt JA, Bratincsak A, Eusebi F, Sherman LS, Mattson MP, Martin R, Roa MS. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol 2007; 66: 637-49. IF 2009: 4.6

Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202:445-55. IF ‘09: 14.5

Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible costimulator and ICOS-L in IBM muscle: significance for CD8+ T cell cytotoxicity. Brain 2004; 127:1182-90. IF ‘09: 9.5

Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-904. IF 2009: 9.5

Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, Gold R, Hunig, T. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003; 140: 143-52. IF 2008: 2.8

Schmidt J, Metselaar JM, Gold R. Intravenous Liposomal Prednisolone Downregulates In Situ TNF-alpha Production by T-cells in Experimental Autoimmune Encephalomyelitis. J Histochem Cytochem 2003; 51: 1241-4. IF 2009: 2.4

Schmidt J, Sturzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001; 65: 59-67. IF 2009: 3.0

Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431-41. IF 2009: 9.5

Wohlleben G, Ibrahim SM, Schmidt J, Toyka KV, Hartung HP, Gold R. Regulation of Fas and FasL expression on rat Schwann cells. Glia 2000; 30: 373-81. IF 2009: 4.9

 

Übersichtsartikel

Dohrn MF, Auer‑Grumbach M, Baron R, Birklein F, Escolano‑Lozano F, Geber C, Grether N, Hagenacker T, Hund E, Sachau J, Schilling M, Schmidt J, Schulte‑Mattler W, Sommer C, Weiler M, Wunderlich G, Hahn K. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature. J Neurol 2020 (online ahead of print, 1-16) IF 2019: 4.0.

Schilling M, Auer-Grumbach M, Baron R, Birklein F, Escolano-Lozano F, Dohrn MF, Geber C, Grether N, Hagenacker T, Hahn K, Lehmann HC, Sachau J, Schmidt J, Schulte-Mattler W, Sommer C, Weiler M, Hund E. Hereditäre Transthyretinamyloidose (ATTRv-Amyloidose): Neues zu Therapieoptionen und neurologische Empfehlungen zu Untersuchungsmanagement und -standards in Deutschland und Österreich. DGNeurologie 2020; 3(5): 369-383. Kein IF.

Schoser B, Baum P, Boentert M, Dillmann K, Emmer A, Knauss S, Enax-Krumova E, Grosskreutz J, Güttsches A, Hellwig K, Holzapfel K, Kornblum C, Lehmann H, Melms A, Meyer T, Petri S, Pilgram L, Reiners K, Saak A, Schäfer J, Schmidt J, Schneider-Gold C, Schons M, Urban PP, Vorgerd M, Young P, Zierz S. SARS-CoV-2/COVID-19 und neuromuskuläre Erkrankungen: Bestandsaufnahme der DGN (Deutsche Gesellschaft für Neurologie) Kommission Motoneuron- und neuromuskuläre Erkrankungen. DGNeurologie 2020; 3(4):310-320. Kein IF.

Zeng R, Schmidt J. Impact and Management of Dysphagia in Inflammatory Myopathies. Curr Rheumatol Rep 2020; 22(10):74 (1-11) IF 2019: 3.9

Meyer S, Zechel S, Schmidt J, Schröter C, Zschüntzsch J. Adulte und nicht-infektiöse Myositiden – Übersicht und Therapie. Neurol Rehabil 2020; 26(1): 32-45. IF: 0.09

Glaubitz S, Zeng R, Schmidt J. New insights into the treatment of myositis. Therap Adv Musculoskel Dis 2020; 12:1759720X19886494. IF2018: 5.1

Glaubitz S, Zeng R, Zschüntzsch J, Schmidt J. Neuropathien beim Diabetiker - Nicht immer ist der Zucker Schuld. Internistische Praxis. Zeitschrift für die gesamte Innere Medizin. 2019: 61(1):101-111. IF 2018: 0.02

Glaubitz S, Schmidt K, Zschüntzsch J, Schmidt J. Myalgia in myositis and myopathies. Best Practice & Research Clinical rheumatology (ELS) 2019;33(3): 101433. IF 2018: 3.0

Fitzner M, Schmidt J. Neuromuskuläre Erkrankungen: Leitsymptom Muskelschwäche. Der Allgemeinarzt 2018; 8: 22-25.

Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 2018; 5(2): 109-129. (no IF)

Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol 2018; 14: 255-268. IF 2016: 12.2

Schmidt K, Schmidt J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr Op Rheum 2017; 29(6): 632-638). IF 2016: 4.5

Keller CW, Schmidt J, Lünemann JD. Immune and Myodegenerative Pathomechanisms in Inclusion Body Myositis. Ann Clin Transl Neurol 2017; 4(6): 422-445. (IF 2017: 3.9)

Zschüntzsch J, Preusse C, Ruck T, Meuth SG, Müller-Felber W, Stenzel W, Schmidt J. Myositis Netz – Darstellung des klinisch-wissenschaftlichen Verbundes und Aktuelles zur Diagnostik und Therapie entzündlicher Muskelerkrankungen. Nervenheilkunde 2017; 36: 48–54; IF 2012: 0,3.

Fitzner M, Schmidt J. Entzündliche Muskelerkrankungen – Aktueller Stand zur Diagnostik und Therapie der Myositis. Aktuel Rheumatol 2016; 41: 232-242. IF 2013: 0.06

Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler N, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H. Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges 2016; 14: 321–338. IF: 2,0

Breithaupt M, Schmidt J. Treatment strategies for inclusion body myositis. Expert Opin Orphan Drugs 2014; 2: 1255-1265.

Breithaupt M, Schmidt J. Diagnostik und Therapie von Myositiden - Zertifizierte Fortbildung. NeuroTransmitter 2014; 25: 46-55.

Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin. Exp. Immunol. 2014; 175: 349–358. IF: 3,4

Schmidt J, Dalakas MC. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev. Clin. Immunol. 2013; 9: 1125–1133. IF: 3.3

Breithaupt M, Schmidt J. Current essentials in inflammatory myopathies. EMJ Neurol. 2013; 1:46-51.

Breithaupt M, Schmidt J. Update on Treatment of Inclusion Body Myositis. Curr Rheumatol Rep 2013; 15: 329 (1-6). IF: 2.5

Schmidt J, Vorgerd M. Therapiestandard bei Myositiden und Muskeldystrophien. Nervenarzt 2011; 82: 723-732. IF: 0.8

Schmidt J, Dalakas MC. Inclusion body myositis in the elderly: an update. Aging Health 2010; 6:687-94.

Schmidt J. Of amyloid and inflammation: causes of chronic muscle disease. E-Neuroforum 2010:81-8

Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn 2010; 4: 241-250.

Schmidt J. Pathogenese der Einschlusskörperchenmyositis: Stellenwert der Entzündung und Bedeutung für Therapiestrategien. Akt Neurol 2009; 36: 121-125.

Lunemann JD, Schmidt J, Dalakas MC, Munz C. Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Autophagy 2007; 3: 384-386. IF: 12.0

Grauer O, Offenhausser M, Schmidt J, Toyka KV, Gold R. Glukokortikosteroid-Therapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktische Empfehlungen. Nervenarzt 2001; 72: 577-589. IF: 0.8

 


Leitung: